Dyslipidemia and the preventive potential in the Greenlandic population.
Arctic health
Cholesterol
Epidemiology
Plasma lipid
Statins
Journal
Atherosclerosis plus
ISSN: 2667-0895
Titre abrégé: Atheroscler Plus
Pays: Netherlands
ID NLM: 9918249514806676
Informations de publication
Date de publication:
Mar 2023
Mar 2023
Historique:
received:
06
09
2022
revised:
25
10
2022
accepted:
19
12
2022
entrez:
27
3
2023
pubmed:
28
3
2023
medline:
28
3
2023
Statut:
epublish
Résumé
Low-density lipoprotein cholesterol (LDL-C) is a well-established risk factor for development of cardiovascular diseases. Based on available clinical data, we aimed to investigate the plasma lipid profile in the Greenlandic population, the proportion on cholesterol-lowering treatment and the adherence to local indications for cholesterol-lowering therapy. This is an observational cross-sectional study of the adult (≥21 years) Greenlandic population with focus on clinically determined lipid levels from 2017 to early 2022. We investigated levels of dyslipidemia and assessed cholesterol-lowering medication usage in individuals with an indication according to current Greenlandic guidelines, which include a) LDL-C >5 mmol/l, b) diabetes, c) diagnosed atherosclerotic disease and 4) a SCORE2 >7.5%. In the adult Greenlandic population of 40,565 individuals a lipid profile was available in 13,895 with a mean LDL-C of 3.0 mmol/L and 976 (7%) had a LDL-C >5 mmol/l. One or more indications for cholesterol-lowering medication was present in 3988 individuals and a total of 5464 adult Greenlanders either fulfilled local criteria for statin therapy or received a statin (some without current indication) and among these, 2232 (41%) individuals received no statin. These findings indicate that clinically significant dyslipidemia is common in the adult Greenlandic population and that the cardiovascular preventive potential of cholesterol-lowering therapy is currently underutilized.
Sections du résumé
Background
UNASSIGNED
Low-density lipoprotein cholesterol (LDL-C) is a well-established risk factor for development of cardiovascular diseases. Based on available clinical data, we aimed to investigate the plasma lipid profile in the Greenlandic population, the proportion on cholesterol-lowering treatment and the adherence to local indications for cholesterol-lowering therapy.
Methods
UNASSIGNED
This is an observational cross-sectional study of the adult (≥21 years) Greenlandic population with focus on clinically determined lipid levels from 2017 to early 2022. We investigated levels of dyslipidemia and assessed cholesterol-lowering medication usage in individuals with an indication according to current Greenlandic guidelines, which include a) LDL-C >5 mmol/l, b) diabetes, c) diagnosed atherosclerotic disease and 4) a SCORE2 >7.5%.
Results
UNASSIGNED
In the adult Greenlandic population of 40,565 individuals a lipid profile was available in 13,895 with a mean LDL-C of 3.0 mmol/L and 976 (7%) had a LDL-C >5 mmol/l. One or more indications for cholesterol-lowering medication was present in 3988 individuals and a total of 5464 adult Greenlanders either fulfilled local criteria for statin therapy or received a statin (some without current indication) and among these, 2232 (41%) individuals received no statin.
Conclusion
UNASSIGNED
These findings indicate that clinically significant dyslipidemia is common in the adult Greenlandic population and that the cardiovascular preventive potential of cholesterol-lowering therapy is currently underutilized.
Identifiants
pubmed: 36969703
doi: 10.1016/j.athplu.2022.12.003
pii: S2667-0895(22)00061-X
pmc: PMC10037086
doi:
Types de publication
Journal Article
Langues
eng
Pagination
22-27Informations de copyright
© 2022 The Authors.
Déclaration de conflit d'intérêts
The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Henning Bundgaard reports receiving lecture fees from MSD, BMS, Amgen and Sanofi. Marit E Jørgensen reports receiving research grants from AMGEN, Astra Zeneca, Boehringer Ingelheim, 10.13039/501100004191Novo Nordisk and Sanofi Aventis and holds shares in 10.13039/501100004191Novo Nordisk A/S. The remaining authors report no conflicts of interest.
Références
Atherosclerosis. 2004 Jun;174(2):391-8
pubmed: 15136072
Arterioscler Thromb. 1992 Dec;12(12):1371-9
pubmed: 1450169
Eur Heart J. 2021 Jul 1;42(25):2455-2467
pubmed: 34120185
Lancet. 1971 Jun 5;1(7710):1143-5
pubmed: 4102857
Lancet. 2005 Oct 8;366(9493):1267-78
pubmed: 16214597
Eur Heart J. 2020 Jul 21;41(28):2618-2628
pubmed: 32702746
Am J Clin Nutr. 1980 Dec;33(12):2657-61
pubmed: 7435433
Lipids Health Dis. 2020 May 25;19(1):108
pubmed: 32450855
Int J Circumpolar Health. 2022 Dec;81(1):2030522
pubmed: 35086441
Circ Cardiovasc Qual Outcomes. 2017 Jul;10(7):
pubmed: 28698192
Lancet. 2010 Nov 13;376(9753):1670-81
pubmed: 21067804
Int J Epidemiol. 1997 Dec;26(6):1182-90
pubmed: 9447397
Eur J Clin Nutr. 2000 Sep;54(9):732-7
pubmed: 11002386
Eur Heart J. 2016 Jul 01;37(25):1944-58
pubmed: 27122601
Ugeskr Laeger. 2009 Mar 23;171(13):1093
pubmed: 19321088
JAMA. 2018 Apr 17;319(15):1566-1579
pubmed: 29677301
Eur Heart J. 2021 Jul 1;42(25):2439-2454
pubmed: 34120177
Nutr Metab Cardiovasc Dis. 2010 Jun;20(5):350-8
pubmed: 19800772
Can J Cardiol. 2014 Aug;30(8):864-8
pubmed: 25064579
Eur Heart J. 2017 Aug 21;38(32):2473-2479
pubmed: 28077470
Atheroscler Suppl. 2020 Dec;42:e1-e5
pubmed: 33589218
NCHS Data Brief. 2014 Dec;(177):1-8
pubmed: 25536410
Nat Rev Cardiol. 2021 Oct;18(10):689-700
pubmed: 33833450
Circulation. 2014 Jun 24;129(25 Suppl 2):S1-45
pubmed: 24222016
Eur J Prev Cardiol. 2016 Jul;23(10):1093-103
pubmed: 26040999
HGG Adv. 2022 Jun 09;3(4):100118
pubmed: 36267056
Int J Circumpolar Health. 2005 Sep;64(4):387-95
pubmed: 16277122
Can J Cardiol. 2015 Sep;31(9):1116-23
pubmed: 26239003
Eur Heart J. 2017 Aug 21;38(32):2459-2472
pubmed: 28444290
Eur Heart J. 2020 Jan 1;41(1):111-188
pubmed: 31504418
Age Ageing. 2021 Feb 26;50(2):554-558
pubmed: 32936863
Eur J Prev Cardiol. 2016 Jul;23(11):NP1-NP96
pubmed: 27353126
Nat Genet. 2017 Dec;49(12):1722-1730
pubmed: 29083407
Int J Circumpolar Health. 2018 Dec;77(1):1422668
pubmed: 29384037
Atherosclerosis. 2003 Feb;166(2):351-7
pubmed: 12535749
Medicina (Kaunas). 2014;50(1):44-53
pubmed: 25060204